Posts by Sandra Ansanay-Alex
ONWARD Medical secures €40 million
ONWARD Medical has successfully raised more than €40 million in a capital increase, marking a significant milestone in its mission to restore movement and independence in people with spinal cord injuries. The financing round includes a €25 million investment from EQT Life Sciences, alongside strong support from leading institutional and sector-specialist investors. This new funding…
Read MoreThree Life Sciences Companies Finalist of the Strategis Award
The jury of the Prix Strategis selected five companies, to advance to the final round of the competition. Three of them are Swiss Health Valley projects. Irmos Technologies AG, which develops solutions to extend the lifespan of infrastructure. Neology SA, which offers a clean alternative to diesel. Virtuosis AI, specialized in intelligent vocal biomarkers. Isospec…
Read MoreEPFL Innogrants
Five EPFL-based life sciences startups, Alpion CryoSolutions, Eleum, Feedback Intuitive, MOLECL, and NourishAI are the latest recipients of the EPFL Startup Launchpad Innogrant and Innogrant for biotherapeuthics. Each team has secured CHF 100,000 to accelerate the development of their technology. Alpion CryoSolutions Cryo-electron microscopy has transformed biology by allowing researchers to see proteins in extraordinary detail. However, existing…
Read MoreAC Immune and Eli Lilly Sign New Agreement Worth CHF 10 Million
Eli Lilly has handed Vaud-based AC Immune (Switzerland) 10 million Swiss francs ($12.5 million) to expand their Alzheimer’s disease collaboration as a candidate moves closer to the clinic. The U.S. pharma first tapped up AC Immune in a 2018 deal that included an $81 million upfront fee. That pact, which came with up to 1.7 billion francs ($2.1 billion)…
Read MoreTerapet Launches FLASHVIVO to Enable Real-Time Verification in FLASH Therapy
Gevena-based start-up and CERN spinoff Terapet SA has announced the launch of FLASHVIVO, a new collaborative research and development project designed to tackle one of the most critical challenges facing the clinical adoption of FLASH radiotherapy: the lack of real-time, in vivo treatment verification under ultra-high dose rate conditions. FLASH radiotherapy has emerged as a…
Read MoreOculis Announces European Medicines Agency PRIME Designation for Privosegtor
Oculis Holding AG, based in canton of Vaud and Zug, has received a significant regulatory boost for its neuroprotective candidate Privosegtor, with the European Medicines Agency (EMA) granting the therapy Priority Medicines (PRIME) designation for the treatment of optic neuritis (ON). Optic neuritis is a rare and sight-threatening condition that can occur as a relapse…
Read MoreBIND 2026 Crowns Four Life Sciences Winners
Four Swiss Health Gems won several awards during BIND – BioInnovation Day 2026. Dexterous Endoscope won the Best Start-Up Award, PreciMune got the Best Academic Project Award. Impli AG and MoleSense won support from H4 and CSEM.
Read MoreAI for Cardiology: Two UNIGE Researchers at the Heart of an European Project
The ARGENTIC project, funded by Horizon Europe, has just secured €7.5 million to develop a sovereign, energy-efficient AI system — to be rolled out across 19 institutions in 9 countries. Elena Tessitore and Douglas Teodoro, from University of Geneva (UNIGE), will lead the healthcare pillar. Elena Tessitore (HUG / Faculty of Medicine, UNIGE) and Douglas…
Read MoreGioele La Manno Receives the 2026 Boehringer Ingelheim–FENS Research Award
The Federation of European Neuroscience Societies (FENS), in partnership with Boehringer Ingelheim, has announced that Gioele La Manno is the recipient of the prestigious Boehringer Ingelheim–FENS Research Award 2026. The award, worth CHF 25,000, recognises outstanding contributions to neuroscience and will be officially presented at the FENS Forum 2026, taking place from 6–10 July 2026…
Read MorebioMérieux Invests CHF 1 Million in Plair
bioMérieux announces an investment of more than one million Swiss Francs in Plair, a Geneva-based and University of Geneva spinoff offering a breakthrough solution for real-time microbial detection and air sampling. As part of its commitment to advancing environmental control to help improve patient and consumer health, bioMérieux invested in Plair, a Company headquartered in Geneva, Switzerland.…
Read More